Navigation Links
Polaris Enrolls First Patient in Phase 2 Clinical Trial of ADI-PEG 20 for the Treatment of Malignant Mesothelioma
Date:3/18/2011

SAN DIEGO, March 18, 2011 /PRNewswire/ -- Polaris Group announced today the enrollment of the first patient in a Phase 2 clinical trial of ADI-PEG 20 (pegylated arginine deiminase), the company's novel enzyme-based treatment for malignant mesothelioma. This randomized trial, called "ADAM" (Arginine Deiminase And Mesothelioma), will evaluate the treatment efficacy of ADI-PEG 20 as a single agent compared to the best supportive care. The primary endpoint of the study is progression free survival.

Peter Szlosarek, M.D., Ph.D., of the Centre for Experimental Cancer Medicine, Barts Cancer Institute, Queen Mary University of London, is the lead investigator of the study. "It is with great anticipation that the ADAM trial has opened at Barts and other cancer centers in the U.K., including hospitals in Belfast, Cambridge, Hull, Manchester and Southampton," said Dr. Szlosarek. "We are pleased to be joining Polaris Group in exploring the potential benefits of ADI-PEG 20 in treatment of different cancers."

Malignant mesothelioma is a cancer of the lungs that frequently occurs in people who have been exposed to asbestos. The disease is usually diagnosed two to three decades after prolonged exposure and when it has generally spread beyond the stage for successful surgical treatment.  The prognosis for patients with late stage malignant mesothelioma is poor with a median survival of less than one year.

Polaris Group scientists and colleagues have been investigating the metabolic enzyme argininosuccinate synthetase (ASS) and its presence or absence in relationship to growth of normal cells and tumor cells.  ASS is required for the production of arginine, an amino acid needed for growth and replication of cells. Normal cells have normal levels of ASS and can produce sufficient arginine for their own growth and survival. However, many types of tumor cells cannot make their own arginine due to a deficiency in ASS and, therefore, must obtain it from e
'/>"/>

SOURCE Polaris Group
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Polaris Group and The Ludwig Institute for Cancer Research Ltd Initiate Phase 2 Trial of Amino-Acid Degrading Enzyme, ADI-PEG 20, in Patients with Small Cell Lung Cancer
2. YM BIOSCIENCES REPORTS DAIICHI-SANKYO ENROLLS FIRST PATIENTS IN PHASE II, FIRST-LINE LUNG CANCER TRIAL WITH NIMOTUZUMAB
3. YM BioSciences enrolls first US patient in Phase II randomized, double-blind brain metastases trial for nimotuzumab
4. China-Biotics, Inc. Announces Conference Call to Discuss First Quarter 2009 Financial Results
5. MEDRAD Installs First Intego(TM) PET Infusion System
6. Pioneering IVF Technique Produces Region's First Pregnancy
7. Immtech Reports Fiscal First Quarter 2009 Results
8. Repair Stem Cell Institute Announces Industrys First Standards of Excellence for Global Stem Cell Treatment Centers to Protect Patients from Less-than-Competent Therapeutics
9. Huifeng Bio-Pharmaceutical (HFGB) Reports over $5 Million in Gross Sales; Record Results for the First Half of 2008
10. China-Biotics, Inc. Reports First Quarter 2009 Financial Results
11. Video: CSL Behring Provides $1.2M Grant for Worlds First Study of Postpartum Women with VWD, Common Bleeding Disorder
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)... Research and Markets ... the "Global Biosimilars Market, 2015 - 2025" ... Global Biosimilars Market, 2015 - 2025, report provides ... market. With the blockbuster biologics losing patent protection ... are being viewed as viable substitutes to the ...
(Date:7/29/2015)... Inc., an early stage biotech startup based on perinatal ... the Musculoskeletal Transplant Foundation of Edison NJ ... round of development of the proprietary AmnioCept™ product line ... AmnioChor,s technology allows cryopreservation of the amniotic membrane of ... those tissues. Amnion is a well-established source of multipotent ...
(Date:7/29/2015)... 2015  Pfenex Inc. (NYSE MKT: PFNX) announced today ... released on Thursday, August 13, 2015, before the open ... will host a conference call to discuss the financial ... outlining the financial results and business update will be ... call 1-866-376-8058 (US) or 1-412-542-4131 (international) and reference Pfenex ...
(Date:7/29/2015)... ... July 29, 2015 , ... The third Medical Innovation Impact Index (MI3) Alert ... particular, drug/device combinations. The current system received a score of 0 (range -10 to ... Innovation (iPCI) of Fairleigh Dickinson University’s ( FDU ) Rothman Institute of Innovation ...
Breaking Biology Technology:Global Biosimilars Market to 2025: Monoclonal Antibodies (mAbs), Insulin, Interferons, G-CSF/ GM-CSF, Erythropoietins and Others 2Global Biosimilars Market to 2025: Monoclonal Antibodies (mAbs), Insulin, Interferons, G-CSF/ GM-CSF, Erythropoietins and Others 3The Musculoskeletal Transplant Foundation Agrees to Invest in AmnioChor 2Pfenex To Report Second Quarter 2015 Results and Provide Business Update on Thursday, August 13, 2015 2Third Medical Innovation Impact Index Issued by Fairleigh Dickinson University’s Initiative for Patient-Centered Innovation (iPCI) 2Third Medical Innovation Impact Index Issued by Fairleigh Dickinson University’s Initiative for Patient-Centered Innovation (iPCI) 3
... turn a profit, and it operates in a biotech space where ... research tool manufacturer NimbleGen Systems to file an initial ... bit of evidence that the Wisconsin biotech company is going places. ... and visibility for NimbleGen, which saw its revenues grow to $13.5 ...
... second time this year, a tech-based company in Wisconsin has ... public. Called an initial public offering, this kind of business ... who are directly involved, but to others who may follow ... company, has filed papers with the Securities and Exchange ...
... Wis . - Every surgical operation requires proper wound ... and a Madison start-up business has received a $100,000 ... , , Nerites Corp ., which develops tissue repair ... received a $100,000 Small Business Innovation Research ...
Cached Biology Technology:IPO-bound NimbleGen traveling in fast company 2IPO-bound NimbleGen traveling in fast company 3IPO-bound NimbleGen traveling in fast company 4Wisconsin IPOs are a harbinger of growing tech economy 2Wisconsin IPOs are a harbinger of growing tech economy 3
(Date:7/9/2015)... Research and Markets( ... "Biometrics for Banking; Market & Technology Analysis, ... their offering. The adoption for banking ... and the forecast is that by 2020 it ... involved in delivering biometric systems to the banking ...
(Date:7/8/2015)... YORK , July 8, 2015 Summary ... globally, and the fourth most fatal, with a mortality ... The poor prognosis of pancreatic cancer patients has highlighted ... treatment, which is not being met by the current ... an array of products with varying molecule types and ...
(Date:7/8/2015)... Florida , July 8, 2015 ... evolving as this summer,s must have products such as wearables, ... demand as popularity for biometrics based devices continues to rapidly ... NXT-ID, Inc. (NASDAQ: NXTD ), Google Inc. (NASDAQ: ... (NYSE: FIT ), GoPro, Inc. (NASDAQ: GPRO ) ...
Breaking Biology News(10 mins):Global Banking Biometrics Market 2015-2020 - Market & Technology Analysis, Adoption Strategies and Forecasts 2Global Banking Biometrics Market 2015-2020 - Market & Technology Analysis, Adoption Strategies and Forecasts 3Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation 2Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation 3Consumers Flock to This Summer's Must Have Tech Gadgets as Latest Digital Wallets, Smart Technology & Wearable Products Continue to Grow in Popularity & Functionality 2Consumers Flock to This Summer's Must Have Tech Gadgets as Latest Digital Wallets, Smart Technology & Wearable Products Continue to Grow in Popularity & Functionality 3Consumers Flock to This Summer's Must Have Tech Gadgets as Latest Digital Wallets, Smart Technology & Wearable Products Continue to Grow in Popularity & Functionality 4Consumers Flock to This Summer's Must Have Tech Gadgets as Latest Digital Wallets, Smart Technology & Wearable Products Continue to Grow in Popularity & Functionality 5Consumers Flock to This Summer's Must Have Tech Gadgets as Latest Digital Wallets, Smart Technology & Wearable Products Continue to Grow in Popularity & Functionality 6
... release is available in German . ... establishment of twelve new Collaborative Research Centres (CRC) beginning 1 ... at its spring meeting in Bonn. The new CRCs will ... 112 million euros (including a 20% programme allowance for indirect ...
... HOUSTON -- (May 28, 2010) -- A team ... critical effects at the heart of the latest high-temperature ... it. In new research appearing online today in ... University-led team offers new evidence about the quantum features ...
... 27, 2010 Ardipithecus ramidus a purported ... the Year" is coming under fire from scientists who ... there were dense woodlands at the African site where the ... abundant evidence for open savanna habitats," says University of Utah ...
Cached Biology News:DFG approves 12 new collaborative research centers 2DFG approves 12 new collaborative research centers 3DFG approves 12 new collaborative research centers 4DFG approves 12 new collaborative research centers 5DFG approves 12 new collaborative research centers 6Zeroing in on quantum effects 2Zeroing in on quantum effects 3Out of the woods for 'Ardi' 2Out of the woods for 'Ardi' 3Out of the woods for 'Ardi' 4